NCT05848336

Brief Summary

To evaluate the efficacy of eight weeks of GFCF in children with ASD on autistic symptoms and ophthalmic findings such as corneal reflex, interpupillary distance (IPD) and pupil size.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 26, 2020

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 14, 2022

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 18, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 26, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 8, 2023

Completed
Last Updated

May 8, 2023

Status Verified

May 1, 2023

Enrollment Period

1.3 years

First QC Date

April 26, 2023

Last Update Submit

May 5, 2023

Conditions

Keywords

gluten free casein free diet

Outcome Measures

Primary Outcomes (3)

  • Gilliam Autism Rating Scale 2 (GARS-2)

    Based on DSM-IV autism diagnostic criteria, GARS-2 is a behavior checklist for children and teenagers aged 3 to 22. The three subscales of the scale are communication, social interaction, and stereotypical behavior. Each subscale contains 14 items that are scored on a four-point scale (0: Never observed, 1: Rarely observed, 2: Sometimes observed, 3: Often observed). The total score obtained from the scale is converted into standard scores, and an OBI score is obtained. An OBI score of 85 and above indicates a high probability of having ASD, a score between 70-84 indicates a medium probability, and a score of 69 and below indicates a low probability.

    8 weeks

  • Weight (kg)

    Body weight was measured in kilograms.

    8 weeks

  • Body mass index

    Body mass index (BMI)=weight/(height)\^2

    8 weeks

Secondary Outcomes (1)

  • The pupil measurements

    8 weeks

Study Arms (1)

Gluten Free Casein Free Diet

EXPERIMENTAL

Foods containing gluten (pasta, bread, etc.), casein (unfermented dairy products), and their disguised sources have been eliminated from the nutrition program. Also, packaged foods (chocolate, crackers, etc.) containing additives such as artificial preservatives, food coloring, and sweeteners that create a tendency to consume in children were avoided from the nutrition program. Goat milk contains type A2 casein, and most of the casein is digested in fermented dairy products. In order to increase calcium intake, the consumption of some foods (dill, kale, spinach, chard, arugula, broccoli, parsley, legumes, nuts, tahini, etc.) has been increased. Elimination was done gradually, considering nervousness, anxiety, etc., due to the effects of opioid mechanisms of action and gastrointestinal system symptoms.

Behavioral: Gluten Free Casein Free Diet

Interventions

Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).

Gluten Free Casein Free Diet

Eligibility Criteria

Age2 Years - 11 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Informed consent / Assent, as applicable must be signed prior to executing any study related procedure
  • Children, male or female, 2 to 11 years old (inclusive)
  • Confirmed diagnosis of ASD according to the DSM-IV Symptom Checklist
  • Ability to maintain a gluten- and casein-free diet during the study

You may not qualify if:

  • Cardiovascular, psychiatric, autoimmune, cancer, etc. children with secondary different disease
  • Children with any drug use
  • Children currently receiving treatment with any alternative medical methods (eg.hyperbaric).
  • Children with a diagnosis of celiac disease
  • Children who have received any dietary treatment before

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Üsküdar University

Istanbul, 34672, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Autism Spectrum Disorder

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof.

Study Record Dates

First Submitted

April 26, 2023

First Posted

May 8, 2023

Study Start

November 26, 2020

Primary Completion

March 14, 2022

Study Completion

January 18, 2023

Last Updated

May 8, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations